AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
CA-125 ELEVATIONS IN PATIENTS WITH MALIGNANT-LYMPHOMAS
Authors: FEHM T BECK E VALERIUS T GRAMATZKI M JAGER W
Citation: T. Fehm et al., CA-125 ELEVATIONS IN PATIENTS WITH MALIGNANT-LYMPHOMAS, Tumor biology, 19(4), 1998, pp. 283-289
EVALUATING ANTIBODIES FOR THEIR CAPACITY TO INDUCE CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS
Authors: WURFLEIN D DECHANT M STOCKMEYER B TUTT AL HU PS REPP R KALDEN JR VANDEWINKEL JGJ EPSTEIN AL VALERIUS T GLENNIE M GRAMATZKI M
Citation: D. Wurflein et al., EVALUATING ANTIBODIES FOR THEIR CAPACITY TO INDUCE CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS, Cancer research, 58(14), 1998, pp. 3051-3058
IMMUNOTHERAPY OF B-CELL MALIGNANCIES VIA [FC-ALPHA-RIXCD20] DIRECTED BISPECIFIC ANTIBODIES
Authors: STOCKMEYER B DECHANT M REPP R VALERIUS T DEO Y GRAZIANO R KALDEN JR GLENNIE M VANDEWINKEL JGJ GRAMATZKI W
Citation: B. Stockmeyer et al., IMMUNOTHERAPY OF B-CELL MALIGNANCIES VIA [FC-ALPHA-RIXCD20] DIRECTED BISPECIFIC ANTIBODIES, British Journal of Haematology, 102(1), 1998, pp. 85-85
RENAL DYSFUNCTION IN A HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENT WHO WAS TREATED WITH INDINAVIR
Authors: GRUNKE M VALERIUS T MANGER B KALDEN JR HARRER T
Citation: M. Grunke et al., RENAL DYSFUNCTION IN A HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENT WHO WAS TREATED WITH INDINAVIR, Clinical infectious diseases, 25(5), 1997, pp. 1270-1271
HLA CLASS-II ANTIBODIES RECRUIT G-CSF ACTIVATED NEUTROPHILS FOR TREATMENT OF B-CELL MALIGNANCIES
Authors: VALERIUS T ELSASSER D REPP R VANDEWINKEL JGJ GRAMATZKI M GLENNIE M
Citation: T. Valerius et al., HLA CLASS-II ANTIBODIES RECRUIT G-CSF ACTIVATED NEUTROPHILS FOR TREATMENT OF B-CELL MALIGNANCIES, Leukemia & lymphoma, 26(3-4), 1997, pp. 261
BISPECIFIC ANTIBODY MDX210 (FC-GAMMA-RI X HER-2 NEU) IN COMBINATION WITH G-CSF - RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH METASTATIC BREAST-CANCER/
Authors: VALERIUS T STOCKMEYER B REPP R DEO Y VANOIJK H VANDEWINKEL JG KALDEN JR GRAMATZKI M
Citation: T. Valerius et al., BISPECIFIC ANTIBODY MDX210 (FC-GAMMA-RI X HER-2 NEU) IN COMBINATION WITH G-CSF - RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH METASTATIC BREAST-CANCER/, European journal of cancer, 33, 1997, pp. 676-676
ACTIVATED NEUTROPHILS AS EFFECTOR-CELLS FOR BISPECIFIC ANTIBODIES
Authors: VALERIUS T WURFLEIN D STOCKMEYER B
Citation: T. Valerius et al., ACTIVATED NEUTROPHILS AS EFFECTOR-CELLS FOR BISPECIFIC ANTIBODIES, Cancer immunology and immunotherapy, 45(3-4), 1997, pp. 142-145
CLINICAL-EVALUATION OF THE BISPECIFIC ANTIBODY MDX-H210 (ANTI-FC-GAMMA-RI-X-ANTI-HER-2 NEU) IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR (FILGRASTIM) FOR TREATMENT OF ADVANCED BREAST-CANCER/
Authors: VANOJIK HH REPP R GROENEWEGEN G VALERIUS T VANDEWINKEL JGJ
Citation: Hh. Vanojik et al., CLINICAL-EVALUATION OF THE BISPECIFIC ANTIBODY MDX-H210 (ANTI-FC-GAMMA-RI-X-ANTI-HER-2 NEU) IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR (FILGRASTIM) FOR TREATMENT OF ADVANCED BREAST-CANCER/, Cancer immunology and immunotherapy, 45(3-4), 1997, pp. 207-209
FC-ALPHA-RI (CD89) AS A NOVEL CYTOTOXIC TRIGGER MOLECULE FOR BISPECIFIC ANTIBODIES
Authors: STOCKMEYER B VALERIUS T REPP R DEO Y VANSPIEK A KALDEN JR VANDEWINKEL JGJ GRAMATZKI M
Citation: B. Stockmeyer et al., FC-ALPHA-RI (CD89) AS A NOVEL CYTOTOXIC TRIGGER MOLECULE FOR BISPECIFIC ANTIBODIES, Experimental hematology, 25(8), 1997, pp. 560-560
GENERATION OF HER-2 NEU-SPECIFIC CYTOTOXIC NEUTROPHILS IN-VIVO - EFFICIENT ARMING OF NEUTROPHILS BY COMBINED ADMINISTRATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND FC-GAMMA RECEPTOR-I BISPECIFIC ANTIBODIES/
Authors: HEIJNEN IAFM RIJKS LJM SCHIEL A STOCKMEYER B VANOJIK HH DECHANT M VALERIUS T KELER T TUTT AL GLENNIE MJ VANROYEN EA CAPEL PJA VANDEWINKEL JGJ
Citation: Iafm. Heijnen et al., GENERATION OF HER-2 NEU-SPECIFIC CYTOTOXIC NEUTROPHILS IN-VIVO - EFFICIENT ARMING OF NEUTROPHILS BY COMBINED ADMINISTRATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR AND FC-GAMMA RECEPTOR-I BISPECIFIC ANTIBODIES/, The Journal of immunology, 159(11), 1997, pp. 5629-5639
ANTIBODIES AS SPECIFIC ANTICANCER AGENTS - WISHFUL THINKING OR REAL POSSIBILITY
Authors: GRAMATZKI M VALERIUS T
Citation: M. Gramatzki et T. Valerius, ANTIBODIES AS SPECIFIC ANTICANCER AGENTS - WISHFUL THINKING OR REAL POSSIBILITY, Der Internist, 38(11), 1997, pp. 1055-1062
PRECLINICAL STUDIES WITH FC-GAMMA-R BISPECIFIC ANTIBODIES AND GRANULOCYTE-COLONY-STIMULATING FACTOR-PRIMED NEUTROPHILS AS EFFECTOR-CELLS AGAINST HER-2 NEU OVEREXPRESSING BREAST-CANCER/
Authors: STOCKMEYER B VALERIUS T REPP R HEIJNEN IAFM BUHRING HJ DEO YM KALDEN JR GRAMATZKI M VANDEWINKEL JGJ
Citation: B. Stockmeyer et al., PRECLINICAL STUDIES WITH FC-GAMMA-R BISPECIFIC ANTIBODIES AND GRANULOCYTE-COLONY-STIMULATING FACTOR-PRIMED NEUTROPHILS AS EFFECTOR-CELLS AGAINST HER-2 NEU OVEREXPRESSING BREAST-CANCER/, Cancer research, 57(4), 1997, pp. 696-701
FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY
Authors: VALERIUS T STOCKMEYER B VANSPRIEL AB GRAZIANO RF VANDENHERIKOUDIJK IE REPP R DEO YM LUND J KALDEN JR GRAMATZKI M VANDEWINKEL JGJ
Citation: T. Valerius et al., FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY, Blood, 90(11), 1997, pp. 4485-4492
FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY
Authors: VALERIUS T STOCKMEYER B VANSPRIEL AB GRAZIANO RF VANDENHERIKOUDIJK IE REPP R DEO YM KALDEN JR VANDEWINKEL JGJ GRAMATZKI M
Citation: T. Valerius et al., FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY, Blood, 90(10), 1997, pp. 2927-2927
BIFUNCTIONAL NHS-BAT ESTER FOR ANTIBODY CONJUGATION AND STABLE TC-99MLABELING - CONJUGATION CHEMISTRY, IMMUNOREACTIVITY AND KIT FORMULATION
Authors: EISENHUT M LEHMANN WD BECKER W BEHR T ELSER H STRITTMATTER W STEINSTRASSER A BAUM RP VALERIUS T REPP R DEO Y
Citation: M. Eisenhut et al., BIFUNCTIONAL NHS-BAT ESTER FOR ANTIBODY CONJUGATION AND STABLE TC-99MLABELING - CONJUGATION CHEMISTRY, IMMUNOREACTIVITY AND KIT FORMULATION, The Journal of nuclear medicine, 37(2), 1996, pp. 362-370
IN-VIVO BLOCKADE OF TNF-ALPHA BY INTRAVENOUS-INFUSION OF A CHIMERIC MONOCLONAL TNF-ALPHA ANTIBODY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - SHORT-TERM CELLULAR AND MOLECULAR EFFECTS
Authors: LORENZ HM ANTONI C VALERIUS T REPP R GRUNKE M SCHWERDTNER N NUSSLEIN H WOODY J KALDEN JR MANGER B
Citation: Hm. Lorenz et al., IN-VIVO BLOCKADE OF TNF-ALPHA BY INTRAVENOUS-INFUSION OF A CHIMERIC MONOCLONAL TNF-ALPHA ANTIBODY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - SHORT-TERM CELLULAR AND MOLECULAR EFFECTS, The Journal of immunology, 156(4), 1996, pp. 1646-1653
CELL-ADHESION MOLECULES COOPERATE WITH FC-GAMMA-RI IN ADCC OF G-CSF PRIMED NEUTROPHILS AGAINST BREAST-CANCER CELLS
Authors: STOCKMEYER B VALERIUS T REPP R DEO Y VANDEWINKEL JGJ KALDEN JR GRAMATZKI M
Citation: B. Stockmeyer et al., CELL-ADHESION MOLECULES COOPERATE WITH FC-GAMMA-RI IN ADCC OF G-CSF PRIMED NEUTROPHILS AGAINST BREAST-CANCER CELLS, Blood, 88(10), 1996, pp. 2864-2864
EVALUATING B-CELL ANTIBODIES FOR THEIR CAPACITY TO MEDIATE ADCC
Authors: VALERIUS T WURFLEIN D STOCKMEYER B REPP R DEO Y WEINER G KALDEN JR VANDEWINKEL JGJ GLENNIE M GRAMATZKI M
Citation: T. Valerius et al., EVALUATING B-CELL ANTIBODIES FOR THEIR CAPACITY TO MEDIATE ADCC, Blood, 88(10), 1996, pp. 339-339
HLA CLASS-II AS POTENTIAL TARGET ANTIGEN ON MALIGNANT B-CELLS FOR THERAPY WITH BISPECIFIC ANTIBODIES IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR
Authors: ELASSER D VALERIUS T REPP R WEINER GJ DEO Y KALDEN JR VANDEWINKEL JGJ STEVENSON GT GLENNIE MJ GRAMATZKI M
Citation: D. Elasser et al., HLA CLASS-II AS POTENTIAL TARGET ANTIGEN ON MALIGNANT B-CELLS FOR THERAPY WITH BISPECIFIC ANTIBODIES IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR, Blood, 87(9), 1996, pp. 3803-3812
EVALUATING B-CELL PANEL ANTIBODIES IN ADCC WITH G-CSF NEUTROPHILS AS EFFECTOR-CELLS
Authors: VALERIUS T WURFLEIN D ELSASSER D STOCKMEYER B REPP R WEINER G GLENNIE M KALDEN JR VANDEWINKEL JGJ GRAMATZKI M
Citation: T. Valerius et al., EVALUATING B-CELL PANEL ANTIBODIES IN ADCC WITH G-CSF NEUTROPHILS AS EFFECTOR-CELLS, Tissue antigens, 48(4-II), 1996, pp. 111-111
CELL-ADHESION MOLECULES IN ADCC OF G-CSF PRIMED NEUTROPHILS
Authors: STOCKMEYER B VALERIUS T REPP R DEO Y VANDEWINKEL JGJ KALDEN JR GRAMATZKI M
Citation: B. Stockmeyer et al., CELL-ADHESION MOLECULES IN ADCC OF G-CSF PRIMED NEUTROPHILS, Tissue antigens, 48(4-II), 1996, pp. 514-514
PHASE-I TRIAL OF MDX210 (BISPECIFIC ANTIBODY FC-GAMMA-RI X HER-2 NEU)IN COMBINATION WITH G-CSF IN PATIENTS WITH BREAST-CANCER/
Authors: REPP R VALERIUS T WIELAND G OETZEL C DEO Y VANDEWINKEL JG KALDEN JR LANG N GRAMATZKI M
Citation: R. Repp et al., PHASE-I TRIAL OF MDX210 (BISPECIFIC ANTIBODY FC-GAMMA-RI X HER-2 NEU)IN COMBINATION WITH G-CSF IN PATIENTS WITH BREAST-CANCER/, Blood, 86(10), 1995, pp. 2017-2017
HLA CLASS-II AS POTENTIAL TARGET ANTIGEN ON MALIGNANT B-CELLS FOR THERAPY WITH BISPECIFIC ANTIBODIES IN COMBINATION WITH G-CSF
Authors: VALERIUS T REPP R ELSASSER D WURFLEIN D WEINER GJ DEO Y KALDEN JR VANDEWINKEL JJG GLENNIE MJ GRAMATZKI M
Citation: T. Valerius et al., HLA CLASS-II AS POTENTIAL TARGET ANTIGEN ON MALIGNANT B-CELLS FOR THERAPY WITH BISPECIFIC ANTIBODIES IN COMBINATION WITH G-CSF, Blood, 86(10), 1995, pp. 2132-2132
MUTATION OF THE LEF-1 BINDING-SITE IN THE ENHANCER OF THE ADENOSINE-DEAMINASE GENE DISRUPTS POSITION-INDEPENDENT EXPRESSION IN TRANSGENIC MICE
Authors: HAYNES T VALERIUS T POTTER S WIGINTON D
Citation: T. Haynes et al., MUTATION OF THE LEF-1 BINDING-SITE IN THE ENHANCER OF THE ADENOSINE-DEAMINASE GENE DISRUPTS POSITION-INDEPENDENT EXPRESSION IN TRANSGENIC MICE, The FASEB journal, 8(7), 1994, pp. 10001271-10001271
ANTIBODY-BASED THERAPEUTIC APPROACH TO B-CELL MALIGNANCIES WITH NEUTROPHILS AS POTENTIAL EFFECTOR-CELLS
Authors: VALERIUS T ELSASSER D REPP R STOCKMEYER B KALDEN JR GRAMATZKI M
Citation: T. Valerius et al., ANTIBODY-BASED THERAPEUTIC APPROACH TO B-CELL MALIGNANCIES WITH NEUTROPHILS AS POTENTIAL EFFECTOR-CELLS, Blood, 84(10), 1994, pp. 10000036-10000036
Risultati: 1-25 | 26-26